BM
VKTX icon

Brandywine Managers’s Viking Therapeutics VKTX Stock Holding History

Brandywine Managers’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$480K Hold
12,301
– – 0.24% 37
2026
Q1 		$400K Hold
12,301
– – 0.24% 33
2025
Q4 		$433K Hold
12,301
– – 0.21% 30
2025
Q3 		$323K Buy
12,301
+4,219
+52% +$126K 0.31% 31
2025
Q2 		$214K Buy
+8,082
New +$213K 0.21% 33
2025
Q1 		– Sell
-8,082
Closed -$325K – 37
2024
Q4 		$325K Hold
8,082
– – 0.34% 29
2024
Q3 		$512K Buy
+8,082
New +$474K 0.55% 25

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Brandywine Managers's VKTX Position: Q2 2026 in Review

Brandywine Managers held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 12,301 shares worth $480K. The position accounts for 0.24% of the portfolio, ranked #37.

Brandywine Managers first reported a position in VKTX in Q3 2024 and has held it in 7 quarters since. The position peaked at $512K in Q3 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Brandywine Managers held 12,301 shares of Viking Therapeutics worth $480K as of Q2 2026.
  • Brandywine Managers left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up 0.24% of Brandywine Managers's portfolio in Q2 2026, its #37 holding.
  • Brandywine Managers first reported a position in Viking Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Brandywine Managers's Viking Therapeutics position peaked at $512K in Q3 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Brandywine Managers's 13F filing for Q2 2026, filed 14 Aug 2026.